Key Takeaways
- Steady 18% H1 revenue growth, no fireworks: Revenue grew 18% YoY in H1 FY24 and 15% in Q2, with EPS hitting a post-listing high of INR12.54. The quarter was a clean execution story across all verticals.
- Injectables facility is mechanically complete: The new injectables line finished mechanical installation by quarter-end and has entered validation, positioning the company for a new revenue stream starting next fiscal year.
- Working capital reset to pre-IPO levels: Working capital days improved to 33, driven by process efficiencies and subsiding supply chain volatility. Management targets a sustained 30-40 day range.
- Exports surged 130% on a small base: The export vertical grew 130% YoY in H1, with a strategy to grow both organically via own filings and inorganically by acquiring market authorizations.
- What to watch next quarter: Progress on injectables validation, any inorganic export moves, and whether CDMO momentum sustains the pickup seen over the last three quarters.
CDMO & Trade Generics Momentum
- CDMO pickup is structural, not seasonal: The last three quarters have shown a pickup in CDMO growth because long-term efforts on adding customers and products are now converting into numbers. A strong leadership team is in place and delivering results.
- No inherent seasonality: Q1 and Q3 were low quarters last year, Q2 and Q4 were strong, but management attributes this to order movement between quarter-end months rather than a pattern. The chronic segment focus means no monsoon-linked antibiotic seasonality.
- Chronic disease tailwind: Lifestyle diseases (cardiovascular, diabetes, neuro, gastro) are rising in India, with more patients in non-metro and smaller towns getting diagnosed and treated. Multi-drug therapy is the mainstay in chronic diseases, increasing product complexity and demand.
- Trade generics expansion continues: The long-term strategy is to expand distribution networks into India's hinterland while enhancing the product range.
- New product pipeline is competitively sensitive: A significant number of new chronic therapy products and fixed-dose combinations are being planned, but management declined to provide qualitative color or contribution splits, citing competitive sensitivity.
Hitesh Windlass: "So, my sense is that in the long run, this will definitely have a positive impact. More demand will be there. And for us, as a business, we will also reap the benefit of that."
Injectables: The Next Growth Leg
- Mechanical completion achieved: The injectables facility finished mechanical installation by end of Q2 FY24. All machinery is installed and quality validations are now ongoing.
- Revenue expected from next fiscal year: Management stated the company is well positioned to discover a fresh revenue avenue from the injectables facility commencing from the next fiscal year.
- Margin profile is attractive: At peak utilization, the injectables business is expected to deliver EBITDA margins of 17-18%, which should lift the overall company EBITDA as the product mix shifts.
- Capex is modest relative to revenue potential: A new facility capable of delivering about INR1,000 crores in turnover will require capex of approximately INR40 crores, with an initial spend of INR20 crores and subsequent INR10 crore tranches as need increases.
Komal Gupta: "Injectables definitely is a higher margin business for us. Then once we reach the peak level, we expect EBITDA margins like 17%, 18% in our injectable business."
Export Vertical: Small Base, Big Ambition
- 130% YoY growth in H1: The export vertical grew 130% YoY, albeit on a small base, driven by sustained progress across all business verticals.
- Dual growth strategy: The company plans to grow exports organically by adding products through own dossier filings, and inorganically by acquiring market authorizations in various geographies or entities that hold such authorizations.
- No feet on the ground: The company operates an asset-light export model with no physical presence in any of its export markets.
- Dossier timeline is long: Developing and filing a dossier takes 6-12 months, followed by another 18-24 months for approval, and only then commercialization. This implies a multi-year lead time before filings convert to revenue.
- Country-level detail withheld: Management declined to provide a country-wise revenue break-up, calling it competitively sensitive.
Hitesh Windlass: "we do not have any feet on the ground in any of these markets."
Margins & Operating Leverage
- Gross margins are sustainable: Current gross margins are sustainable due to improvement in existing verticals and product mix changes. Further growth is possible as the mix continues to evolve toward higher-margin trade generics and exports.
- Operating leverage still to come: With capacity utilization at around 55%, the existing OSD facility can deliver turnover of about INR650 crores. As utilization rises and volume comes in, operating leverage is expected to flow through.
- No annual margin guidance: When asked if 50-100 bps of annual margin expansion is a reasonable assumption for the next 2-3 years, management declined to provide any forward guidance.
- Quality regulation as a margin tailwind: The tightening of Schedule M and WHO GMP norms is expected to weed out non-compliant players, benefiting larger, organized companies with professional talent and quality systems. The company expects to be a beneficiary.
Hitesh Windlass: "the regulators who come to speak have very clearly spoken and said that those companies who are not implementing Schedule M, in letter and spirit, will be weeded out."
Balance Sheet & Working Capital
- Working capital reset to 33 days: Working capital improved to 33 days due to process improvements, internal efficiency drives, and a new leadership team focused on better cash from operations.
- Supply chain volatility has subsided: The working capital increase over the last two years was driven by higher inventory held to ensure uninterrupted supply of chronic-segment brands during supply chain disruption. That pressure has now eased, allowing reduced inventory days.
- Pre-IPO levels are the target: Management is gunning for a sustained 30-40 day working capital range, consistent with pre-IPO levels, and does not expect to return to the elevated post-IPO levels.
Komal Gupta: "Pre-IPO level is the general level. So 30 days, 40 days is a good number that we gun for."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectables revenue commencement | Revenue generation from injectables facility to begin | Next fiscal year (FY25) |
| Injectables peak EBITDA margin | 17-18% EBITDA margin at peak utilization | At peak level (no date) |
| Working capital target | 30-40 days | Sustained, no reversion to post-IPO highs |
| New facility capex | ~INR40 crores total for INR1,000 crore turnover capacity; INR20 crores initial | Phased as need increases |
| Dossier-to-revenue cycle | 6-12 months to file, 18-24 months for approval, then commercialization | Multi-year from filing start |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹153 cr, +15% YoY |
| EBITDA | ₹19 cr, +17% YoY |
| PAT | ₹14 cr, +15% YoY |
| EPS | ₹6.75 |
| H1 FY24 EPS | ₹12.54, +24% YoY, highest since listing |
| H1 operating cash flow | ₹54 cr |
| Liquidity position | ₹167 cr at quarter end |
| CDMO vertical revenue | ₹117.8 cr, +10% YoY |
| Trade generics & institutional revenue | ₹28.3 cr, +23% YoY |
| Export vertical revenue | ₹6.4 cr, +157% YoY |
| Capacity utilization | ~55% |
| Working capital days | 33 days at quarter end |
| Injectable facility capex | ~₹70 cr |